Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$21.06 USD
+0.49 (2.38%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.05 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SNDX 21.06 +0.49(2.38%)
Will SNDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNDX
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
Other News for SNDX
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
First Week of June 21st Options Trading For Syndax Pharmaceuticals (SNDX)
Syndax management to meet with BTIG
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax management to meet with BTIG